On September 4, Novo-Nordisk A/S declined 3.01% in regular trading, trading at $46.075 per share, with turnover of approximately $65.01 million. The stock had plunged as much as 13% in pre-market trading before partially recovering during the session.

The decline was primarily driven by clinical trial data showing that Novo-Nordisk A/S's next-generation obesity drug delivered inferior efficacy compared to Eli Lilly's Zepbound. This setback compounds existing pipeline concerns after the company's IL-6 monoclonal antibody Phase III study failed to meet its primary endpoint in late July, which had already triggered a nearly 10% stock drop. Market anxiety over the company's heavy reliance on semaglutide-based therapies has intensified as Eli Lilly continues to widen its competitive lead with Zepbound, Mounjaro, and a broader next-generation weight-loss pipeline.

Within the Pharmacy sector, major peers also traded lower, with Eli Lilly down 1.44%, AstraZeneca PLC down 1.58%, Pfizer down 1.48%, and Johnson & Johnson down 1.15%, while Akanda Corp bucked the trend with a 14.71% gain.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)